Summaries for patients. Parathyroid hormone (1-84) and risk for spinal fractures in women with osteoporosis.
D015519:Bone Density / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D053565:Hypercalciuria / Q000139:chemically induced; D015994:Incidence; D008159:Lumbar Vertebrae / Q000293:injuries; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012306:Risk; D012680:Sensitivity and Specificity; D016103:Spinal Fractures / Q000453:epidemiology / Q000517:prevention & control*
D010281:Parathyroid Hormone; D011994:Recombinant Proteins